Berry, John W.; Carney, Ross; Lankford, Hal
June 1961
Angiology;Jun1961, Vol. 12 Issue 6, p254
Academic Journal
Twenty-eight patients with ischemic heart disease, as manifest clinically by the anginal syndrome, were studied by a "double-blind" method. The drug tested was isosorbide dinitrate (ISDN). Compared with placebo, there was a 76 per cent difference in the ability to decrease the frequency of the anginal attacks. When compared with a therapeutic standard using penta-erythritol tetranitrate, the difference was not as great. A method of determining ISBN in the blood is reviewed. Appreciable levels were demonstrated in normal volunteers 2 and 3 hours after ingestion of 20 mg of the drug. No attempt to correlate the blood measurements in our patients was made. Other than the "nitrate" headache, no serious toxic reaction was observed. One patient did have exfoliative dermatitis which developed while on therapy and cleared upon discontinuance of the drug. It can be concluded that ISDN appears to be an effective drug for the oral treatment of angina pectoris.


Related Articles

  • Spinal Cord Stimulation Significantly Improves Refractory Angina Pectoris-A Local Experience: Spinal Cord Stimulation in Refractory Angina Chua, Roderick; Keogh, Anne // Heart, Lung & Circulation;Mar2005, Vol. 14 Issue 1, p3 

    Background:: Severe refractory angina pectoris can occur in end-stage coronary artery disease despite maximal medical and revascularization therapy. Spinal cord stimulation is an under-utilized but well-established modality for the treatment of intractable angina pain. Aim:: To illustrate the...

  • Alternative treatments for angina. Lanza, Gaetano A. // Heart;May2007, Vol. 93 Issue 5, p544 

    The author explores the alternative treatments for angina pectoris. Angina pectoris in patients with ischaemic heart disease is commonly treated successfully with anti-ischaemic drugs and percutaneous or surgical coronary interventions. However, angina attacks in some patients are not prevented...

  • Therapeutic Potential of Adult Progenitor Cells in the Management of Chronic Myocardial Ischemia. Raval, Amish N // American Journal of Cardiovascular Drugs;2008, Vol. 8 Issue 5, p315 

    Refractory angina as a result of chronic myocardial ischemia is a common and disabling condition. Adult progenitor cells have emerged as a potential revolutionary treatment for cardiovascular disease. Locally administered adult progenitor cells with particular vasculogenic potential may offer...

  • Diagnostic accuracy of technician supervised and reported exercise tolerance tests. Muir, D. F.; Jummun, M.; Stewart, D. J.; Clark, A. L. // Heart;Apr2002, Vol. 87 Issue 4, p381 

    This article focuses on a study related to the diagnostic accuracy of technician supervised and reported exercise tolerance tests. Ischaemic heart disease is a common condition with an annual hospital admission rate in England and Wales of around 6.3 per 1000. All tests were performed to Bruce...

  • THE PATHOPHYSIOLOGY OF MYOCARDIAL ISCHAEMIA. Crossman, David C. // Heart;May2004, Vol. 90 Issue 5, p576 

    Myocardial ischaemia is responsible for angina, unstable angina, and, less commonly, shortness of breath secondary to ischaemic left ventricular dysfunction as well as cardiac arrhythmias. This article will deal with the mechanisms of myocardial ischaemia likely to be encountered in patients...

  • The Efficacy of Guanxinning Injection in Treating Angina Pectoris: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Yongliang Jia; Siu-wai Leung; Ming-Yuen Lee; Guozhen Cui; Xiaohui Huang; Fongha Pan // Evidence-based Complementary & Alternative Medicine (eCAM);2013, Vol. 2013, p1 

    Objective. The randomized controlled trials (RCTs) on Guanxinning injection (GXN) in treating angina pectoris were published only in Chinese and have not been systematically reviewed. This study aims to provide a PRISMA-compliant and internationally accessible systematic review to evaluate the...

  • Preprocedural statin therapy reduces the risk and extent of cardiac biomarker release following percutaneous coronary intervention. Veselka, Josef; Proch�zkov�, ��rka; Duchonov�, Radka; Homolov�, Ingrid; Tesar, David; Bybee, Kevin A. // Heart & Vessels;May2006, Vol. 21 Issue 3, p146 

    This study evaluates the association between statin therapy in patients treated by percutaneous coronary intervention (PCI) for stable angina pectoris and postinterventional myocardial injury with subsequent long-term clinical outcome. Prospectively collected data on 400 consecutive patients...

  • Ticlopidine Treatment Before Percutaneous Coronary Intervention in Patients With Stable Angina Pectoris. Veselka, Josef; Procházková, Sárka; Duchonová, Radka; Bolomová, Ingrid; Fedorová, Lenka; Tesar, David // Journal of Applied Research;Fall2003, Vol. 3 Issue 4, p434 

    Purpose: Platelet inhibition reduces periprocedural cardiac events in patients referred to percutaneous coronary intervention (PCI). In patients with stable angina pectoris, there is no reliable evidence that pretreatment with ticlopidine (Ticlid) plus aspirin decreases adverse cardiac events...

  • Myocardial ischaemia in patients with frequent angina pectoris. Selwin, Andrew P.; Fox, Kim; Eves, Martin; Oakley, David; Dargie, Henry; Shillingford, John // British Medical Journal;12/9/1978, Vol. 2 Issue 6152, p1594 

    Focuses on the study of myocardial ischaemia in patients with frequent angina pectoris. Importance of recording electrocardiograph evidence; Etiology of ischaemia; Pathophysiology of angina pectoris.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics